The Study
Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
This study watched what happened to 59 people after they started taking a new medicine, and noticed their blood numbers changed. But it didn't compare them to people who didn't take the medicine, so we can't be sure the medicine caused the changes.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
A medicine called liraglutide was given to obese people with type 2 diabetes who weren't controlling their blood sugar well. After 14 weeks, their blood sugar dropped, they lost a little weight and fat, and their body made insulin better.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 540 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1These changes suggest better blood sugar control and improved insulin function, which could help prevent diabetes complications, though the exact meaning of increased visfatin and resistin is unclear.
- 2HbA1c dropped by 0.9%, BMI dropped by 1.4 kg/m², body fat dropped by 0.5%.
- 3HOMA-IR (insulin resistance) improved from 8.4 to 4.6.
- 4HOMA-B (insulin production) rose from 48.2 to 87.6.
- 5Visfatin and resistin levels went up.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetes research and clinical practice
Year
2014
Authors
G. Díaz-Soto, D. D. de Luis, Rosa Conde-Vicente, Olatz Izaola-Jáuregui, C. Ramos, E. Romero
Related Content
Claims (5)
Liraglutide enhances insulin sensitivity and glucose control in people with obesity and prediabetes by acting through a biological pathway that is different from weight loss or the body's natural incretin system, as shown by blocking GLP-1 receptors reversing the effect and sitagliptin having no effect.
In overweight or obese adults with type 2 diabetes not fully controlled by metformin or metformin plus sulfonylurea, 14 weeks of liraglutide at up to 1.8 mg per day reduces HbA1c by 0.9%, BMI by 1.4 kg/m², and total body fat mass by 0.5%.
In overweight or obese adults with type 2 diabetes, 14 weeks of liraglutide treatment is associated with lower insulin resistance and higher insulin secretion, reflecting improved pancreatic beta-cell function and insulin sensitivity.
In overweight or obese adults with type 2 diabetes, taking liraglutide for 14 weeks results in higher blood levels of visfatin and resistin, two proteins involved in inflammation and insulin signaling.
In overweight or obese adults with type 2 diabetes, higher levels of visfatin in the blood at the start of treatment are linked to lower fasting blood glucose levels.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.